



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kenneth K. Sokoll

Group Art Unit: 1642

Serial No.: 10/076,674

Examiner: TBA

Filed: February 14, 2002

For: STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

RECEIVED
APR 08 2002
TECH CENTER 1600/2900

Sir:

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) _____, filed _____, respectively.

- ☒ This document is being filed within three (3) months of the filing date of the application
- ☐ A check for the requisite fee of \$180 is enclosed.
- ☐ This document is being concurrently filed with the above-identified application
- ☐ This document is being concurrently filed with an Request for Continued Examination (RCE)
- ☐ This document is being filed prior to a first Office Action
- ☐ This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 1151-4172. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: April 1, 2002

By: Maria C.H. Lin
Maria C.H. Lin
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



Docket No. 1151-4172

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kenneth K. Sokoll

Group Art Unit: 1642

Serial No.: 10/076,674


Examiner: TBA

Filed: February 14, 2002

For: STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM

IDS COVER SHEET 1 of 4

1	4,938,763	Dunn RL, et al.,
2	5,126,141	Henry RL
3	5,135,751	Henry RL
4	5,149,543	Cohen S, et al.,
5	5,562,909	Allcock HR, et al
6	5,656,611	Kabanov AV, et al.,
7	5,700,459	Krone V, et al.
8	5,702,716	Dunn RL, et al
9	5,759,551	Ladd AE, et al.,
10	5,763,160	Wang CY
11	6,025,468	Wang CY
12	6,090,388	Wang CY
13	6,107,021	Wang CY, et al.,
14	6,194,388 B1	Kreig AM, et al
15	6,207,646 B1	Kreig AM, et al
16	WO 91/04052	



1151-4172

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kenneth K. Sokoll

Group Art Unit: 1642

Serial No.: 10/076,674

Examiner: TBA

Filed: February 14, 2002

For: STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM

IDS COVER SHEET 2 of 4

- 17 WO 93/01286
- 18 WO 99/52549
- 19 WO 99/66950
- 20 WO 99/66957
- 21 WO 99/67293
- 22. Aguado MT, et al., Immunobiol, 1992, 184:113-125
- 23. Aguiar JC, et al. Vaccine, 2002, 20:275-280
- 24. Ak asaka T, et al., Bioconjugate Chem., 2001, 12:776-785
- 25. Ballico M, et al., Bioconjug Chem, 2001, 12:719-725
- 26. Bjellqvist B, et al., Electrophoresis, 1993, 14:1023-1031

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Kenneth K. Sokoll

Group Art Unit: 1642

Serial No.: 10/076,674

Examiner: TBA

Filed: February 14, 2002

For: STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM

IDS COVER SHEET 4 of 4

58. Romera SA, et al., Vaccine, 2001, 19:132-141
59. Scharton-Kersten T, et al. Infect Immun, 2000, 68:5306-5313
60. Shen F, et al., Vaccine, 1999, 17:3039-3049
61. Suharyono, et al. Lancet, 1992, 340:689-694
62. Visscher GE, et al., J Biomed Mater Res, 1985, 19:349-365
63. Wang CY, USSN 09/865,294, 2001
64. Wang CY, USSN 09/747802, 2001
65. Wang CY, et al., Proc. Nat. Acad. Sci., USA, 1999, 96:10367-10372
66. Weeratna RD, et al., Vaccine, 2000, 18:1755-1762
67. Wright JC, et al., J Controlled Release, 2001, 75:1-10
68. www.expasy.ch/tools/pi_tool.html

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kenneth K. Sokoll

Group Art Unit: 1642

Serial No.: 10/076,674

Examiner: TBA

Filed: February 14, 2002

For: STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM

IDS COVER SHEET 3 of 4

27. Chu RS, et al., J Exp Med, 1997, 186:1623-1631
28. Cox JC, et al. Vaccine, 1997, 15:248-256
29. DesNoyer JR, et al., J Controlled Release, 2001, 70:285-294
30. Eldridge JH, et al., Mol Immunol, 1991, 28:287-297
31. Forbes RT, et al., J Pharm Sci, 1998, 87:13161321
32. Graham PD, et al., J Controlled Release, 1999, 58:233-245
33. Hanson CV, et al., J. Clin Microbiol, 1990, 28:2030-2034
34. Higaki M, et al., Vaccine, 1998, 16:741-745
35. Hilbert AK, et al., Vaccine, 1999, 17:1065-1073
36. Ikada Y, et al., J Bioactive Compat Polym, 1986, 1:32-46
37. Jepson MA, et al. J Drug Targeting, 1993, 1:245-249
38. Jones TR, et al., Vaccine, 1999, 17:3065-3071
39. Kabanov AV, et al., Bioconjug Chem, 1995, 6:7-20
40. Klinman DM, et al., Vaccine, 1999, 17:19-25
41. Klinman DM, et al., Infect Immun, 1999, 67:5658-5663
42. Kreuter J, et al. Vaccine, 1986, 4:125-129
43. Krieg AM, et al., Nature 1995, 374:546-549
44. LiCalsi C, et al., Vaccine, 1999, 17:1796-1803
45. MacDonald RC, et al., Biochim Biophys Acta, 1991, 1061:297-303.
46. Manning MC, et al. Pharmaceutical Research, 1989, 6:903-918
47. Mascotti DP, et al., Proc Nat Acad Sci, USA, 1990, 87:3142-3146
48. Matsuo K, et al. Vaccine, 2000, 18:1344-1350
49. McCluskie MJ, et al., Vaccine, 2000, 18:231-237
50. Moldoveanu Z, et al., J Infect Dis, 1993, 167:84-90
51. Monfardini C, et al., Bioconjugate Chem., 1998, 9:418-450
52. Nagel KM, et al., Pharmacotherapy, 1993, 13:177-188
53. Overcashier DE, et al., J Pharm Sci, 1999, 88:688-695
54. Papisov IM, et al., Advances in Polymer Science, 1988, 90, 1988,139-177
55. Park TG, et al., J Controlled Release, 1995, 33:211-222
56. Powell MF, et al., Pharmaceutical Biotechnology, Vol. 6, Plenum Press, New York, 1995
57. Roberts MJ, et al., J Pharm Sci, 1998, 87:1440-1445



INFORMATION DISCLOSURE CITATION

Attorney Docket:

1151-4172

Serial No.:

10/076,674

Applicant:

Kenneth K. Sokoll

Filing Date:

February 14, 2002

Group Art Unit:

1642

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Name	Class	Sub-Class	Filing Date
	4,938,763		Dunn RL, et al.,			
	5,126,141		Henry RL			
	5,135,751		Henry RL			
	5,149,543		Cohen S, et al.,			
	5,562,909		Allcock HR, et al			
	5,656,611		Kabanov AV, et al.,			
	5,700,459		Krone V, et al.			
	5,702,716		Dunn RL, et al			
	5,759,551		Ladd AE, et al.,			
	5,763,160		Wang CY			
	6,025,468		Wang CY			
	6,090,388		Wang CY			
	6,107,021		Wang CY, et al.,			
	6,194,388 B1		Kreig AM, et al			
	6,207,646 B1		Kreig AM, et al			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translation
	WO 91/04052		PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 93/01286		PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/52549		PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/66950		PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/66957		PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/67293		PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER DOCUMENTS (continued)

	Aguado MT, et al., <u>Immunobiol</u> , 1992, 184:113-125
	Aguiar JC, et al. <u>Vaccine</u> , 2002, 20:275-280
	Akasaka T, et al., <u>Bioconjugate Chem.</u> , 2001, 12:776-785
	Ballico M, et al., <u>Bioconjug Chem</u> , 2001, 12:719-725
	Bjellqvist B, et al., <u>Electrophoresis</u> , 1993, 14:1023-1031
	Chu RS, et al., <u>J Exp Med</u> , 1997, 186:1623-1631
	Cox JC, et al. <u>Vaccine</u> , 1997, 15:248-256
	DesNoyer JR, et al., <u>J Controlled Release</u> , 2001, 70:285-294
	Eldridge JH, et al., <u>Mol Immunol</u> , 1991, 28:287-297
	Forbes RT, et al., <u>J Pharm Sci</u> , 1998, 87:13161321
	Graham PD, et al., <u>J Controlled Release</u> , 1999, 58:233-245
	Hanson CV, et al., <u>J. Clin Microbiol</u> , 1990, 28:2030-2034

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1019

INFORMATION DISCLOSURE

APR 01 2002

PATENT OFFICE

Attorney Docket:
1151-4172Serial No.:
10/076,674Applicant:
Kenneth K. SokollFiling Date:
February 14, 2002Group Art Unit:
1642

OTHER DOCUMENTS (continued)

Higaki M, et al., Vaccine, 1998, 16:741-745

Hilbert AK, et al., Vaccine, 1999, 17:1065-1073

Ikada Y, et al., J Bioactive Compat Polym, 1986, 1:32-46

Jepson MA, et al. J Drug Targeting, 1993, 1:245-249

Jones TR, et al., Vaccine, 1999, 17:3065-3071

Kabanov AV, et al., Bioconjug Chem, 1995, 6:7-20

Klinman DM, et al., Vaccine, 1999, 17:19-25

Klinman DM, et al., Infect Immun, 1999, 67:5658-5663

Kreuter J, et al., Vaccine, 1986, 4:125-129

Krieg AM, et al., Nature 1995, 374:546-549

LiCalsi C, et al., Vaccine, 1999, 17:1796-1803

MacDonald RC, et al., Biochim Biophys Acta, 1991, 1061:297-303

Manning MC, et al. Pharmaceutical Research, 1989, 6:903-918

Mascotti DP, et al., Proc Nat Acad Sci, USA, 1990, 87:3142-3146

Matsuo K, et al., Vaccine, 2000, 18:1344-1350

McCluskie MJ, et al., Vaccine, 2000, 18:231-237

Moldoveanu Z, et al., J Infect Dis, 1993, 167:84-90

Monfardini C, et al., Bioconjugate Chem., 1998, 9:418-450

Nagel KM, et al., Pharmacotherapy, 1993, 13:177-188

Overcashier DE, et al., J Pharm Sci, 1999, 88:688-695

Papisov IM, et al., Advances in Polymer Science, 1988, 90, 1988,139-177

Park TG, et al., J Controlled Release, 1995, 33:211-222

Powell MF, et al., Pharmaceutical Biotechnology, Vol. 6, Plenum Press, New York, 1995

Roberts MJ, et al., J Pharm Sci, 1998, 87:1440-1445

Romera SA, et al., Vaccine, 2001, 19:132-141

Scharton-Kersten T, et al. Infect Immun, 2000, 68:5306-5313.

Shen F, et al., Vaccine, 1999, 17:3039-3049.

Suharyono, et al. Lancet, 1992, 340:689-694.

Visscher GE, et al., J Biomed Mater Res, 1985, 19:349-365

Wang CY, USSN 09/865,294, 2001

Wang CY, USSN 09/747802, 2001

Wang CY, et al., Proc. Nat. Acad. Sci., USA, 1999, 96:10367-10372

Weeratna RD, et al., Vaccine, 2000, 18:1755-1762

Wright JC, et al., J Controlled Release, 2001, 75:1-10

www.expasy.ch/tools/pi_tool.html

RECEIVED

APR 06 2002

TECH CENTER 1600/2900

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.



Docket No. 1151-4172

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kenneth K. Sokoll

Group Art Unit: 1642

Serial No.: 10/076,674

Examiner: TBA

Filed: February 14, 2002

For: STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

RECEIVED
APR 08 2002
TECH CENTER 1600/2900

Sir:

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) _____, filed _____, respectively.

- ☒ This document is being filed within three (3) months of the filing date of the application
- ☐ A check for the requisite fee of \$180 is enclosed.
- ☐ This document is being concurrently filed with the above-identified application
- ☐ This document is being concurrently filed with an Request for Continued Examination (RCE)
- ☐ This document is being filed prior to a first Office Action
- ☐ This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 1151-4172. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: April 1, 2002

By: Maria C.H. Lin

Maria C.H. Lin
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile